project id: TCGA-PRAD; case submitter id: TCGA-XK-AAJP; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.56; rna integrity number: 9.1; age at index: 66; days to birth: -24320; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1945; age at diagnosis: 24320; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1259.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 1008; days to sample procurement: 0; initial weight: 10.0; sample id: ec6a094b-d876-4b92-be62-8833ca961229; sample submitter id: TCGA-XK-AAJP-01A; portion id: a0b573e1-9848-44c1-8ec0-46b75a6d576c; portion submitter id: TCGA-XK-AAJP-01A-11; slide id: d61d88e0-5514-46c0-a197-8dc04a47a82d; slide submitter id: TCGA-XK-AAJP-01Z-00-DX1; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 5.0; percent stromal cells: 25.0; percent tumor cells: 70.0; percent tumor nuclei: 90.0; section location: TOP;